Biotech Values

[jq1234]

I am NOT talking about ultimate outcome, just temporary outcome as I do believe eventually ponatinib will come back to market for very limited patient population. FDA rarely approves drug without clear dosing guidance on label, leave physicians to experiment themselves. So it isn't foregone conclusion at all given what we have now.